Contrast-enhanced CT in the differential diagnosis of bladder cancer and paraganglioma.

Abstract

We sought to summarize the value of contrast-enhanced computed tomography (CECT) in the differential diagnosis of bladder paraganglioma (BPG) and bladder cancer. The medical records of 19 patients with BPG (13 males, 6 females) and 56 patients with bladder cancer (49 males, 7 females) between November 2007 and June 2023 were retrospectively reviewed. All patients underwent unenhanced and contrast-enhanced CT scanning. Patient age (46.4 ± 11.1years vs. 58.6 ± 16.0years), tumor calcification (1/19 vs. 18/56), stalk (0/19 vs. 10/56), internal vessels (15/19 vs. 19/56) and the enlarged adjacent supplying artery (14/19 vs. 10/56) were significantly different between BPG and bladder cancer (P < 0.05). The CT value in the corticomedullary phase (92.4 ± 16.6HU vs. 64.0 ± 14.5HU) and the contrast-enhanced value in the corticomedullary phase (54.5 ± 17.4HU vs. 28.5 ± 12.8HU) were significantly greater in BPG patients than in bladder cancer patients (P < 0.001), with corresponding area under the curve values of 0.930 and 0.912, respectively. The optimal cutoff values were 83.2HU and 38.5HU, respectively. A CT value > 83.2HU in the corticomedullary phase and a contrast-enhanced CT value > 38.5 HU in the corticomedullary phase were used to indicate BPG with sensitivities of 78.9% and 89.5%, respectively, and specificities of 94.6% and 75.0%, respectively. The corticomedullary phase of CECT plays an important role in the preoperative differential diagnosis of BPG and bladder cancer.